AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$52.03 USD
+0.17 (0.33%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$52.03 USD
+0.17 (0.33%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Centene's (CNC) Contract Win to Aid Nebraska's Medicaid Members
by Zacks Equity Research
The Nebraska DHHS awards a contract to Centene's (CNC) Nebraska arm to continue serving the unmet need of the state's Medicaid members with a suite of better healthcare options.
PerkinElmer's (PKI) New Benchtop Platform to Boost Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why Investors Should Hold Myriad Genetics (MYGN) Now
by Zacks Equity Research
Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.
ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
by Zacks Equity Research
The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod
by Zacks Equity Research
Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.
Bruker (BRKR) Gains From New Product Bookings Amid Competition
by Zacks Equity Research
Bruker's (BRKR) revenue recognition from one gigahertz class NMR system and continued uptake of the timsTOF platform hold promise.
Walgreens Boots' (WBA) Product Expansion Aids Amid Rivalry
by Zacks Equity Research
Sales contributions from Walgreens Boots' (WBA) newly-formed Walgreens Health segment instill investors' optimism.
Here's Why Investors Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.
PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance
by Zacks Equity Research
PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.
Abbott (ABT) Reports Favorable Findings From RELIEF Study
by Zacks Equity Research
The latest data from the RELIEF Study suggests a lower rate of hospitalizations from serious diabetes-related events with Abbott's (ABT) FreeStyle Libre system.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and solid prospects in the RCM space raise optimism about the stock.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Medtronic (MDT) Gets FDA's 510(k) Nod for Pediatric ICM
by Zacks Equity Research
This latest approval broadens Medtronic's scope within its Cardiovascular Diagnostics and Services wing within broader Cardiovascular business.
Zacks.com featured highlights AMN Healthcare Services, Encore Wire, Tecnoglass and SP Plus
by Zacks Equity Research
AMN Healthcare Services, Encore Wire, Tecnoglass and SP Plus have been highlighted in this Screen of The Week article.
AMN Healthcare Services (AMN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $107.61, moving +0.7% from the previous trading session.
Charles River (CRL) Gains From Growing Demand Amid Macro Woes
by Zacks Equity Research
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.
McKesson (MCK) Stock Pares Gains Following Rx Savings Buyout
by Zacks Equity Research
McKesson (MCK) agrees to buy privately-held Rx Savings Solutions in alignment with its strategic plan of creating accessible and affordable treatment options.
Here's Why You Should Retain Stryker (SYK) Stock For Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Zimmer Biomet (ZBH) to Offer New Shoulder Replacement System
by Zacks Equity Research
Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.